[Form 4] Lixte Biotechnology Holdings, Inc. Warrants Insider Trading Activity

Rhea-AI Filing Summary

Peter Stazzone, appointed Chief Financial Officer of Lixte Biotechnology Holdings, Inc., was granted options to buy 50,000 shares of common stock at an exercise price of $4.45 per share. The options vest in four equal tranches: 25% on 09/01/2025, 25% on 12/15/2025, 25% on 03/15/2026, and 25% on 06/15/2026, subject to continuous service and possible acceleration on certain events. Each option covers one share and the options expire five years after the grant date, making the exercisable common shares underlying the grant 50,000.

Insights

Corporate Governance Expert

TL;DR: New CFO received a standard time-based option package aligning incentives with shareholder value.

The grant of 50,000 stock options at a $4.45 exercise price to the incoming Chief Financial Officer appears structured as typical executive equity compensation with a four-tranche vesting schedule and potential acceleration for predefined events. This ties a portion of the CFO's compensation to future stock performance while preserving retention through multi-date vesting. From a governance perspective, the award size and five-year term are within common practice for smaller public biotech companies, though materiality depends on the company’s outstanding share count which is not provided here.

Compensation Analyst

TL;DR: Option grant incentivizes near-term and medium-term performance but its investor impact is likely limited without share count context.

The option package vests 25% immediately on the effective date and thereafter in three additional scheduled tranches over nine months, creating a mix of immediate and deferred incentive. The exercise price of $4.45 sets the economic hurdle for value creation. Because the filing does not disclose total shares outstanding or percent dilution, assessing the grant’s dilutionary impact is not possible from this form alone. Overall, the structure encourages retention and alignment but appears routine for an executive hire.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stazzone Peter

(Last) (First) (Middle)

680 E. COLORADO BLVD., SUITE 180

(Street)

PASADENA CA 91101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock	$4.45	09/01/2025		A		50,000		09/01/2025	09/01/2030	Common	50,000	$0(1)	50,000	D

Explanation of Responses:

1. Effective September 1, 2025, the reporting person was granted stock options to purchase 50,000 shares vesting vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026., subject to continuous service and acceleration upon the occurrence of certain events. The grant was in connection with the reporting person being appointed as the Company's Chief Financial Officer. The exercise price is $4.45 per share.

	/s/ Peter Stazzone	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.